Condition
    Effectiveness 1/5

    Vanadium for Type 2 Diabetes

    Vanadium is genuinely insulin-mimetic in cells and rodents, but human trials are tiny and uncontrolled, and the doses used far exceed the tolerable upper intake level.

    Overview

    Vanadium is genuinely insulin-mimetic in cells and rodents, but human trials are tiny and uncontrolled, and the doses used far exceed the tolerable upper intake level.

    Verdict

    Not supported

    The mechanism is real and the therapeutic window is not — Cochrane found no rigorous evidence, and effective doses sit above established safety limits.

    How It Works

    Vanadium inhibits protein tyrosine phosphatase 1B, prolonging insulin receptor phosphorylation and increasing glucose uptake independent of insulin secretion.

    Dosing & Protocol

    Typical dose

    Recommended dose
    Not recommended
    Expected timeframe
    Not applicable

    Protocol

    form
    Not applicable
    duration
    Not applicable
    co factor
    The verdict is no. Vanadyl sulfate and sodium metavanadate have been studied at 50-300 mg/day for type 2 diabetes. A Cochrane review found the trials too small and of too poor quality to demonstrate any effect on glycaemic control, and the doses that produced insulin-mimetic effects in animals are close to toxic in humans. Metformin, GLP-1 receptor agonists, SGLT2 inhibitors and dietary change are what control type 2 diabetes.
    titration
    Not applicable
    starting dose
    Not applicable

    Evidence

    What the studies say

    A Cochrane review of vanadium for type 2 diabetes screened the literature and found no randomized controlled trial meeting inclusion criteria, concluding there is no rigorous evidence that vanadium improves glycemic control and that the safety data are inadequate. The frequently cited human studies are open-label series of 5 to 16 participants given 50-300 mg/day of vanadyl sulfate for three to six weeks; several reported improved hepatic and peripheral insulin sensitivity on clamp testing, but with no blinding, no control arm and no durability data. Context matters here: the tolerable upper intake level for adults is 1.8 mg/day, so these trials used 30 to 170 times that amount. Gastrointestinal intolerance occurred in most participants. Vanadium accumulates in bone and kidney with chronic dosing, and animal toxicology raises renal and haematologic concerns. Metformin and other established agents deliver larger, proven effects with characterised safety.

    A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus

    Score: 8/10
    2008
    systematic_review
    n=40

    Smith DM, Pickering RM, Lewith GT

    There was no good evidence that oral vanadium supplementation improved glycaemic control in diabetes and so the routine use of vanadium could not be recommended.

    View source

    Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus

    Score: 6/10
    2000
    rct
    n=16

    Goldfine AB, Patti ME, Zuberi L +3 more

    Modest reductions in fasting glucose occurred only at the higher vanadyl sulfate dose, with dose-limiting gastrointestinal effects.

    View source

    Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes

    Score: 5/10
    2001
    rct
    n=11

    Cusi K, Cukier S, DeFronzo RA +3 more

    Vanadyl sulfate improved hepatic and muscle insulin sensitivity in patients with type 2 diabetes.

    View source

    Safety

    Caveats

    Vanadium is genuinely toxic at supplemental doses, which is the central point here. The tolerable upper intake level for adults is 1.8 mg/day of elemental vanadium, while diabetes studies used doses many times higher, causing nausea, vomiting, diarrhoea, abdominal cramps and green tongue discolouration; kidney damage is documented at high exposure. Do not use it, and never reduce prescribed diabetes medication in favour of a supplement - uncontrolled diabetes causes retinopathy, nephropathy, neuropathy and cardiovascular disease. Contraindicated in kidney disease, pregnancy and breastfeeding. It may add to the glucose-lowering effect of diabetes drugs, risking hypoglycaemia.

    Less likely to help if

    Everyone: no benefit has been shown and the doses studied approach toxicity.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.